The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline recommendations on the use of antiemetics with chemotherapy and radiation.
Alexandria, VA - The American Society of Clinical Oncology (ASCO) has updated its clinical practice guideline recommendations on the use of antiemetics with chemotherapy and radiation. The guideline update, which also reviews the likelihood of various cancer treatments to cause vomiting, will be published in the June 20, 2006, print issue of the Journal of Clinical Oncology.
Since the release of an evidence-based clinical practice guideline on the use of antiemetics in 1999, new research is available on treatments to prevent nausea and vomiting in cancer patients. In addition, new cancer treatments such as trastuzumab, which treats advanced breast cancer, and erlotinib, which treats metastatic pancreatic and non-small cell lung cancer, are less likely to cause nausea and vomiting.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
New Data Emerges from Phase IIb RELIEVE UCCD Study in Ulcerative Colitis and Crohn’s Disease
February 25th 2025Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) achieved higher rates of clinical remission compared to placebo in the advanced therapy-experienced subgroup.